Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Overview[ - collapse ][ - ]
| Purpose | Primary Objective: - To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4). - To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses. Secondary Objectives: - To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1 - To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2 - To determine antitumor activity in Segment 2 |
|---|---|
| Condition | Solid Tumor |
| Intervention | Drug: SAR302503 Drug: omeprazol Drug: metoprolol Drug: midazolam |
| Phase | Phase 1 |
| Sponsor | Sanofi |
| Responsible Party | Sanofi |
| ClinicalTrials.gov Identifier | NCT01585623 |
| First Received | April 13, 2012 |
| Last Updated | March 21, 2013 |
| Last verified | March 2013 |
Tracking Information[ + expand ][ + ]
| First Received Date | April 13, 2012 |
|---|---|
| Last Updated Date | March 21, 2013 |
| Start Date | June 2012 |
| Estimated Primary Completion Date | March 2013 |
| Current Primary Outcome Measures | Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast [Time Frame: predose and up to 24 hours post dose on Days -1, 1, 15 and 16] [Designated as safety issue: No] |
| Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
| Brief Title | Drug Interaction Study of SAR302503 in Patients With Solid Tumor |
|---|---|
| Official Title | An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors |
| Brief Summary | Primary Objective: - To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4). - To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses. Secondary Objectives: - To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1 - To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2 - To determine antitumor activity in Segment 2 |
| Detailed Description | The duration of the study for an individual patient will include a period to assess eligibility (screening period 21 days), followed by a treatment period of at least 15 days of study treatment, and an end-of-treatment visit at least 30 days following the last administration of study drug. However, treatment may continue if patients are receiving benefit and do not have unacceptable toxicity or meet study withdrawal criteria. |
| Study Type | Interventional |
| Study Phase | Phase 1 |
| Study Design | Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Solid Tumor |
| Intervention | Drug: SAR302503 Pharmaceutical form:capsule Route of administration: oral Drug: omeprazol Pharmaceutical form:capsule Route of administration: oral Drug: metoprolol Pharmaceutical form:tablet Route of administration: oral Drug: midazolam Pharmaceutical form:solution Route of administration: oral |
| Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 16 |
| Estimated Completion Date | March 2013 |
| Estimated Primary Completion Date | March 2013 |
| Eligibility Criteria | Inclusion criteria : - Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist - Signed informed consent Exclusion criteria: - Less than 18 years of age. - Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale) - Inability to follow study requirements and schedule - Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy - Serious medical illness at same time of study and/or significantly abnormal lab reports - Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding. - Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug - Continued toxic effects of prior chemotherapy - Evidence of other concurrent active malignancy - Other concurrent serious illness or medical condition - Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker. - Patients with Insulin-Dependent Diabetes Mellitus. - Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH]). - Inadequate organ function - History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
| Gender | Both |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT01585623 |
|---|---|
| Other Study ID Numbers | INT12497 |
| Has Data Monitoring Committee | No |
| Information Provided By | Sanofi |
| Study Sponsor | Sanofi |
| Collaborators | Not Provided |
| Investigators | Study Director: Clinical Sciences & Operations Sanofi |
| Verification Date | March 2013 |
Locations[ + expand ][ + ]
| Investigational Site Number 840004 | Augusta, Georgia, United States, 30912 |
|---|---|
| Investigational Site Number 840001 | Detroit, Michigan, United States, 48201 |
| Investigational Site Number 840002 | Philadelphia, Pennsylvania, United States, 19111 |